Steven Z. Pavletic | Academic Influence

Steven Z. Pavletic's AcademicInfluence.com Rankings

Steven Z. Pavletic

Engineering

#7718

World Rank

#9130

Historical Rank

Electrical Engineering

#2416

World Rank

#2531

Historical Rank

engineering Degrees

Steven Z. Pavletic

Computer Science

#10442

World Rank

#10968

Historical Rank

Computational Linguistics

#2632

World Rank

#2658

Historical Rank

Machine Learning

#4774

World Rank

#4828

Historical Rank

Artificial Intelligence

#5142

World Rank

#5209

Historical Rank

computer-science Degrees

Download Badge

Engineering
Computer Science

Steven Z. Pavletic's Degrees

PhD Computer Science Stanford University
Masters Electrical Engineering University of California, Berkeley

Similar Degrees You Can Earn

Best Online PhD of Computer Science (Doctorates) 2026

Why Is Steven Z. Pavletic Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Steven Z. Pavletic is a Croatian-American physician and researcher in hematology and oncology known for his role in developing consensus guidelines for clinical trials in chronic Graft-versus-host disease .

(See a Problem?)

Steven Z. Pavletic's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. (2005) (3030)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease (2015) (2244)
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. (2005) (1947)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. (2018) (1270)
Risk factors for acute GVHD and survival after hematopoietic cell transplantation. (2012) (511)
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. (2013) (503)
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. (2018) (472)
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. (2016) (468)
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. (2006) (440)
Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. (2011) (303)
Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. (2006) (299)
Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. (2011) (298)
Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. (2015) (283)
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. (2006) (282)
The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. (2017) (267)
Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. (2015) (264)
Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report (2006) (261)
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. (2007) (226)
Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. (2010) (214)
High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. (2003) (211)
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. (2011) (203)
EBMT—NIH—CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment (2018) (196)
NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. (2015) (189)
Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. (2009) (188)
Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. (2008) (179)
Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. (2010) (175)
Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis (2017) (175)
Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. (2004) (167)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. (2015) (164)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. (2006) (160)
Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. (2010) (157)
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. (2009) (156)
Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. (2006) (155)
Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD (2011) (153)
Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. (2011) (152)
Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. (2003) (138)
Oral graft-versus-host disease. (2008) (137)
Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. (2016) (134)
Diagnosis and Treatment of Ocular Chronic Graft-Versus-Host Disease: Report From the German–Austrian–Swiss Consensus Conference on Clinical Practice in Chronic GVHD (2012) (120)
Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. (2005) (114)
Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease (2004) (112)
Utilization of Chimeric Antigen Receptor (CAR) T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B cell non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. (2019) (107)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. (2015) (107)
Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. (2012) (104)
Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. (2009) (102)
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. (2010) (102)
Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. (2005) (93)
Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD) (2010) (93)
Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. (2011) (88)
Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research. (2013) (87)
Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia (2014) (87)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. (2015) (86)
A survey of diagnosis, management, and grading of chronic GVHD. (2002) (85)
Salivary gland involvement in chronic graft-versus-host disease: prevalence, clinical significance, and recommendations for evaluation. (2010) (84)
Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. (2016) (84)
Validation of measurement scales in ocular graft-versus-host disease. (2012) (83)
A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. (2007) (82)
Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells. (2004) (81)
National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis. (2013) (80)
Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. (2019) (80)
Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. (2003) (80)
Chronic graft versus host disease (2006) (77)
Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results (2011) (77)
Chronic graft versus host disease of oral mucosa: review of available therapies. (2006) (76)
Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study (2012) (75)
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT) (2019) (74)
Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. (2008) (73)
Immunotherapy in hematologic malignancies: past, present, and future (2017) (73)
Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease. (2014) (72)
Transplantation's greatest challenges: advances in chronic graft-versus-host disease. (2007) (72)
Prior rituximab correlates with less acute graft‐versus‐host disease and better survival in B‐cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation (2009) (69)
Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD (2011) (69)
Human herpes 6 virus encephalitis complicating allogeneic hematopoietic stem cell transplantation (2013) (68)
Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus (2011) (66)
Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. (2007) (66)
Prognostic factors of chronic graft‐versus‐host disease after allogeneic blood stem‐cell transplantation (2005) (64)
Vulvovaginal Chronic Graft-Versus-Host Disease With Allogeneic Hematopoietic Stem Cell Transplantation (2007) (63)
Are we making progress in GVHD prophylaxis and treatment? (2012) (63)
Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. (2005) (60)
Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research. (2012) (60)
Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation. (2007) (59)
A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change. (2011) (57)
Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. (2016) (57)
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study (2021) (54)
Diagnosis and staging of chronic graft-versus-host disease in the clinical practice. (2011) (54)
Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. (2006) (54)
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report. (2017) (50)
Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity (2011) (50)
The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. (2015) (49)
Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease. (2011) (49)
Assessment of Joint and Fascia Manifestations in Chronic Graft‐Versus‐Host Disease (2014) (49)
Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population (2008) (49)
Novel targets in the treatment of chronic graft-versus-host disease (2017) (48)
Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium (2011) (48)
Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT (2018) (47)
2014 National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: preface to the series. (2005) (47)
Clinical benefit of response in chronic graft-versus-host disease. (2012) (47)
Fluorescence in situ Hybridization Detection of Cytogenetic Abnormalities in B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2004) (47)
Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. (2015) (47)
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes. (2017) (47)
Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients. (2009) (44)
Biomarkers in chronic graft-versus-host disease: quo vadis? (2018) (44)
Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease. (2014) (43)
Oral symptom intensity, health-related quality of life, and correlative salivary cytokines in adult survivors of hematopoietic stem cell transplantation with oral chronic graft-versus-host disease. (2010) (43)
National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. (2011) (43)
Localization of sclerotic-type chronic graft-vs-host disease to sites of skin injury: potential insight into the mechanism of isomorphic and isotopic responses. (2011) (42)
Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants. (2009) (42)
Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium (2013) (42)
Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease (2016) (41)
Acupuncture treatment for persistent hiccups in patients with cancer. (2010) (41)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report (2021) (40)
Late pulmonary complications after allogeneic hematopoietic stem cell transplantation: diagnosis, monitoring, prevention, and treatment. (2012) (39)
Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. (2018) (39)
Quantitative Salivary Proteomic Differences in Oral Chronic Graft-versus-Host Disease (2012) (39)
Use of a novel virus detection assay to identify coronavirus HKU1 in the lungs of a hematopoietic stem cell transplant recipient with fatal pneumonia (2011) (37)
Comparative analysis of FoxP3+ regulatory T cells in the target tissues and blood in chronic graft versus host disease (2014) (37)
Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium. (2013) (35)
Oral Disease Profiles in Chronic Graft versus Host Disease (2015) (35)
Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. (2010) (34)
Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. (2016) (34)
Health-related quality of life in pediatric patients after allogeneic SCT: development of the PedsQL Stem Cell Transplant module and results of a pilot study (2014) (33)
Malnutrition in patients with chronic GVHD (2014) (33)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. (2021) (32)
Thrombocytopenia and hemostatic disorders in chronic graft versus host disease (2009) (31)
Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis. (2018) (31)
Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease (2014) (31)
A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801 (2018) (30)
An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD. (2017) (30)
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. (2013) (30)
Risk factors and characterization of vitiligo and alopecia areata in patients with chronic graft-vs-host disease. (2015) (30)
Uptake and use of recommendations for the diagnosis, severity scoring and management of chronic graft-versus-host disease: An international survey of the EBMT-NCI Chronic GVHD Task Force (2013) (29)
Oral Chronic Graft-vs.-Host Disease Characterization Using the NIH Scale (2012) (29)
Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution. (2018) (29)
Oral Complications of Chronic Graft-Versus-Host Disease. (2019) (29)
Clinical significance of autoantibodies in a large cohort of patients with chronic graft‐versus‐host disease defined by NIH criteria (2015) (29)
Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects. (2009) (28)
Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease (2015) (28)
Autologous hematopoietic stem cell transplantation for autoimmune disease--is it now ready for prime time? (2012) (28)
T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced Lymphoma in a First-in-Humans Clinical Trial (2016) (27)
Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease. (2012) (27)
Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort. (2015) (27)
Recombinant human factor VIIa for alveolar hemorrhage following allogeneic stem cell transplantation. (2014) (27)
Microchimerism in salivary glands after blood- and marrow-derived stem cell transplantation. (2011) (27)
Spiritual well-being in long-term survivors with chronic graft-versus-host disease after hematopoietic stem cell transplantation. (2010) (26)
Chronic Graft-versus-Host Disease - Clinical Manifestations and Therapy (2009) (26)
Genetically identical twin transplantation for chronic lymphocytic leukemia (2007) (25)
Chronic graft-versus-host disease in the era of reduced-intensity conditioning (2007) (25)
Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally (2018) (24)
Analysis of the recovery of cryopreserved and thawed CD34+ and CD3+ cells collected for hematopoietic transplantation (2014) (24)
Target populations in allogeneic hematopoietic cell transplantation for autoimmune diseases--a workshop accompanying: cellular therapy for treatment of autoimmune diseases, basic science and clinical studies, including new developments in hematopoietic and mesenchymal stem cell therapy. (2006) (23)
Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. (2019) (23)
NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD (2014) (23)
Interphase fluorescence in situ hybridization studies for the detection of 9q34 deletions in chronic myelogenous leukemia: a practical approach to clinical diagnosis. (2004) (22)
Chronic Graft versus Host Disease: Interdisciplinary Management: Contents (2009) (22)
A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display. (2009) (22)
Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials. (2008) (22)
Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. (2010) (22)
The role of immune ablation and stem cell transplantation in severe SLE. (2005) (22)
Intensive immunoablation and autologous blood stem cell transplantation in patients with refractory rheumatoid arthritis: the University of Nebraska experience. (2001) (22)
Comorbidity burden in patients with chronic GVHD (2013) (21)
Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research. (2013) (21)
Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD (2014) (21)
Validation of the National Institutes of Health chronic GVHD Oral Mucosal Score using component-specific measures (2014) (21)
High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-vs-host disease (2016) (20)
Magnetic resonance imaging in sclerotic-type chronic graft-vs-host disease. (2009) (20)
The eGVHD App has the potential to improve the accuracy of graft-versus-host disease assessment: a multicenter randomized controlled trial (2018) (20)
Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. (2012) (19)
Treatment of relapse after autologous blood stem cell transplantation for severe rheumatoid arthritis. (2001) (19)
Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis. (2006) (19)
Targeted pretransplant host lymphocyte depletion prior to T‐cell depleted reduced‐intensity allogeneic stem cell transplantation (2004) (18)
Assessment of ovarian function with anti-Müllerian hormone in systemic lupus erythematosus patients undergoing hematopoietic stem cell transplant. (2009) (18)
Nonmyeloablative allogeneic hematopoietic stem cell transplantation for autoimmune disease. (2004) (17)
Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice (2015) (17)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. (2021) (17)
Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study (2013) (17)
The isomorphic response in morphealike chronic graft-vs-host disease. (2008) (16)
Accuracy and usability of the eGVHD app in assessing the severity of graft-versus-host disease at the 2017 EBMT annual congress (2018) (16)
Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation. (2003) (16)
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor with a CD28 Costimulatory Moiety Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma (2017) (16)
Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant: A Nonrandomized Clinical Trial. (2020) (16)
Characterization and Risk Factor Analysis of Osteoporosis in a Large Cohort of Patients with Chronic Graft-versus-Host Disease. (2016) (15)
High prevalence of small- and large-fiber neuropathy in a prospective cohort of patients with moderate to severe chronic GvHD (2016) (15)
Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens. (2014) (15)
Development, preliminary usability and accuracy testing of the EBMT ‘eGVHD App’ to support GvHD assessment according to NIH criteria—a proof of concept (2016) (15)
Amniotic membrane transplantation—a new approach to crossing the HLA barriers in the treatment of refractory ocular graft-versus-host disease (2018) (15)
Extracorporeal photopheresis as a therapy for autoimmune diseases (2015) (14)
Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213) (2020) (14)
Autoimmunity Following Allogeneic Hematopoietic Stem Cell Transplantation (2020) (14)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. (2021) (14)
Glycolytic metabolism of pathogenic T cells enables early detection of GvHD by 13C-MRI. (2020) (14)
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. (2020) (13)
CD56bright natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-versus-host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results (2017) (13)
RAPID VISION LOSS ASSOCIATED WITH FLUDARABINE ADMINISTRATION (2010) (13)
Discordant functional and inflammatory parameters in multiple sclerosis patients after autologous haematopoietic stem cell transplantation (2004) (13)
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies. (2012) (13)
Technology Insight: hematopoietic stem cell transplantation for systemic rheumatic disease (2008) (13)
Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia. (2013) (13)
Haematopoietic stem cell transplantation: indications, clinical developments and future directions (2004) (13)
Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients (2018) (12)
Which questionnaires should we use to evaluate quality of life in patients with chronic graft-vs-host disease? (2016) (12)
Correlation of pretransplant and early post‐transplant response assessment with outcomes after reduced‐intensity allogeneic hematopoietic stem cell transplantation for non‐Hodgkin's lymphoma (2010) (12)
Prognostic factors influencing survival in patients with B‐cell small lymphocytic lymphoma (2004) (12)
Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease (2007) (12)
Prevalence and determinants of fatigue in patients with moderate to severe chronic GvHD (2016) (12)
A randomized phase-2 trial of pomalidomide in subjects failing prior therapy of chronic graft-versus-host disease. (2020) (11)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. (2021) (10)
HLA DR15 antigen status does not impact graft-versus-host disease or survival in HLA-matched sibling transplantation for hematologic malignancies. (2012) (10)
Prevalence of Isolated Joint Involvement in Chronic Graft‐Versus‐Host Disease: Comment on the Article by Inamoto et al (2014) (10)
Rippled skin, fasciitis, and joint contractures. (2008) (10)
Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia. (2020) (10)
Von Willebrand Factor, Factor VIII, and Other Acute Phase Reactants as Biomarkers of Inflammation and Endothelial Dysfunction in Chronic Graft-Versus-Host Disease (2021) (10)
Joint and fascial chronic graft-vs-host disease: correlations with clinical and laboratory parameters (2016) (10)
Strategies to improve long-term outcome in stage IIIB inflammatory breast cancer: multimodality treatment including dose-intensive induction and high-dose chemotherapy. (2009) (10)
The Future of Chronic Graft-Versus-Host Disease: Introduction to the 2020 National Institutes of Health Consensus Development Project Reports. (2021) (10)
Autologous blood as a source of platelet gel for the effective and safe treatment of oral chronic graft‐versus‐host disease (2018) (9)
High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses (2015) (9)
Active thrombopoiesis is associated with worse severity and activity of chronic GVHD (2013) (9)
Donor-Derived Anti-CD19 Chimeric-Antigen-Receptor-Expressing T Cells Cause Regression Of Malignancy Persisting After Allogeneic Hematopoietic Stem Cell Transplantation (2013) (9)
Allogeneic transplantation following failure of autologous transplantation for lymphoma. (1998) (9)
Glycolytic metabolism of pathogenic T cells enables early detection of GvHD by 13C-MRI (2020) (8)
Impaired Bone Mineral Density in Pediatric Patients with Chronic Graft-versus-Host Disease. (2018) (8)
Topical thalidomide gel in oral chronic GVHD and role of in situ cytokine expression in monitoring biological activity (2013) (8)
Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR (2018) (8)
Metabolic reprogramming augments potency of human pSTAT3-inhibited iTregs to suppress alloreactivity. (2020) (8)
Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease—results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health (2020) (8)
NHANES III equations enhance early detection and mortality prediction of bronchiolitis obliterans syndrome after hematopoietic SCT (2014) (7)
Efficacy and Safety of Baricitinib in Refractory Chronic Graft-Versus-Host Disease (cGVHD): Preliminary Analysis Results of a Phase 1/2 Study (2020) (7)
Predictors for Permanent Discontinuation of Systemic Immunosuppression in Severely Affected Chronic Graft-Versus-Host Disease Patients. (2017) (7)
Biology and management of chronic graft-versus-host disease. (2009) (7)
Vitamin D levels and their associations with survival and major disease outcomes in a large cohort of patients with chronic graft-vs-host disease (2016) (7)
High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation. (2003) (7)
Clinical anti-lymphoma activity and toxicity of T cells expressing a novel anti-CD19 chimeric antigen receptor with fully-human variable regions. (2018) (6)
Potential of glycosylation research in graft versus host disease after allogeneic hematopoietic stem cell transplantation. (2016) (6)
Early Diagnosis of Labial Fusion in Women After Allogeneic Hematopoietic Cell Transplant Enables Outpatient Treatment (2017) (6)
No adverse effect of ABVD chemotherapy in a patient with chronic hepatitis C and Hodgkin’s disease (2004) (6)
Introduction to a review series on emerging immunotherapies for hematologic diseases. (2018) (6)
Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers. (2021) (6)
Treatment of high-risk chronic GVHD. (2008) (6)
Interim Analysis of a Phase II Trial of Montelukast for the Treatment of Bronchiolitis Obliterans Syndrome After HSCT Reveals Immunobiology of Disease (2013) (6)
Feasibility and Reproducibility of the New NIH Consensus Criteria To Evaluate Response in Chronic GvHD - A Pilot Study. (2005) (6)
Allogeneic Hematopoietic Stem Cell Transplantation: Does It Have a Place in Treating Hodgkin Lymphoma? (2010) (6)
Development of severe sclerotic chronic GVHD during treatment with dasatinib (2010) (6)
Immunogenicity of HPV Quadrivalent Vaccine in Women after Allogeneic HCT is Comparable to Healthy Volunteers (2018) (6)
Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease (cGVHD): A Randomized Phase II Study from the Blood and Marrow Transplant Clinical Trials Network (2016) (5)
Towards a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force. (2022) (5)
Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy (2021) (5)
Calcinosis Cutis in the Setting of Chronic Skin Graft-Versus-Host Disease. (2020) (5)
IL-2, the next best thing in chronic GVHD therapy? (2016) (5)
Chronic graft-vs-host disease in 2016: a major challenge and an opportunity (2016) (5)
Allogeneic T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor Cause Remissions of B-Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation without Causing Graft-Versus-Host Disease (2015) (5)
Elevated BAFF Is Correlated with Inflammatory Processes in Chronic Graft Versus Host Disease and Supports Increases in Transitional B Cells (2008) (5)
Rehabilitation interventions in the multi-disciplinary management of patients with sclerotic graft-versus-host disease of the skin and fascia. (2020) (5)
45: Development of Antibodies to Self Antigens K-alpha-1 Tubulin and Collagen V in Patients with Chronic Graft Versus Host Disease (2008) (5)
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Consensus Recommendations for Subsequent Neoplasms (2017) (5)
Salivary ZG16B expression loss follows exocrine gland dysfunction related to oral chronic graft-versus-host disease (2021) (5)
Deciphering the Mystery: Extracorporeal Photopheresis in Graft-versus-Host Disease. (2015) (5)
Syk and tired of current chronic GVHD therapies. (2015) (5)
Spiritual Well-Being in Long-Term Survivors with Chronic Graft versus Host Disease after Hematopoietic Stem Cell Transplant (HSCT) (2012) (5)
Blood stem cells as therapy for severe lupus (2005) (4)
CD69+ resident memory T cells are associated with graft‐versus‐host disease in intestinal transplantation (2020) (4)
Umbilical Cord Blood-Derived Mesenchymal Stromal Cells for Reducing Chronic Graft-Versus-Host Disease After Haploidentical Transplantation: Just Another Labor-Intensive Strategy, or Showing the Way? (2016) (4)
Clinical characteristics and cytokine biomarkers in patients with chronic graft‐vs‐host disease persisting seven or more years after diagnosis (2020) (4)
Granulocytic invasion of the central nervous system after hematopoietic stem cell transplantation for systemic lupus erythematosus. (2006) (4)
Ocular surface indicators and biomarkers in chronic ocular graft-versus-host disease: a prospective cohort study (2021) (4)
Challenges in Conducting Studies in Chronic Graft-versus-Host Disease (2019) (4)
Trends In Incidence, Presentation, and Outcomes Of Chronic Graft-Versus-Host Disease In Allogeneic Transplantation- Report From The Center For International Blood and Marrow Transplant Research (2013) (4)
Accompanying editorial on paper Neutrophil Extracellular Traps (NETs) contribute to Pathological Changes of ocular Graft-vs.-Host Disease (oGVHD) Dry Eye: Implications for novel Biomarkers and Therapeutic Strategies by Seungwon An et al. (2019) (4)
Motor ability, function, and health-related quality of life as correlates of symptom burden in patients with sclerotic chronic graft-versus-host disease receiving imatinib mesylate (2019) (4)
NCCN Guidelines: Pretransplant Recipient Evaluation and Management of Graft-Versus-Host Disease. (2020) (4)
The clinical landscape of chronic graft‐versus‐host disease management in 2021 (2021) (3)
Adoptive Transfer of Treg-Depleted Donor Th1 and Th2 Cells Safely Accelerates Alloengraftment After Low-Intensity Chemotherapy (2010) (3)
Host lymphocyte depletion as a strategy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantation. (2013) (3)
Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host Disease. (2021) (3)
Sarcopenia among patients after allogeneic hematopoietic stem cell transplantation and the impact of chronic graft-versus-host disease (2020) (3)
Meaningful response criteria for myelodysplastic syndromes (2021) (3)
HSCT for AID: entering prime time? (2011) (3)
Identical-Twin Transplants for B-Cell Chronic Lymphocytic Leukemia (B-CLL). (2004) (3)
Upregulation of Interferon-Inducible and Damage Response Receptors in Chronic Graft-Versus-Host Disease (2015) (3)
Chronic GvHD NIH Consensus Project Biology Task Force: Evolving path to personalized treatment of chronic GvHD. (2022) (3)
Considerations when designing a clinical trial of haematopoietic stem cell transplantation for autoimmune disease. (2004) (3)
Elevated Expression of Interferon-Induced Genes and Damage Associated Molecular Pattern Receptor Genes in Chronic Graft Versus Host Disease (2014) (3)
Chronic Graft-Versus-Host Disease Risk Score: A CIBMTR Analysis (2010) (3)
Risk-Factors for Acute Graft-Versus-Host Disease and Survival After Hematopoietic Cell Transplantation From Siblings and Unrelated Donors – An Analysis of the CIBMTR (2010) (3)
A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703 (2020) (2)
Transplantation for SLE (2005) (2)
Clinical Characterization and Cytokine Profile of Fatigue in Hematologic Malignancy Patients with Chronic Graft-Versus-Host Disease (2021) (2)
T-Rapa Cell DLI Safely Balances Th1/Th2 Cytokine Activation After Low-Intensity Allogeneic Hematopoietic Cell Transplantation (2011) (2)
Chronic Graft-Versus-Host Disease (cGVHD) Patients with Bronchiolitis Obliterans Syndrome (BOS) Have Worse Clinical Manifestations and Severity of cGVHD with More Impairment in Self-Assessed Physical and Mental Health than cGVHD Patients without BOS (2012) (2)
National Institutes of Health (NIH) Chronic GVHD Staging in Severely Affected Patients: Organ and Global Scoring Correlate with Established Indicators of Disease Severity and Prognosis (2013) (2)
Long-term follow-up after lymphodepleting autologous hematopoietic cell transplantation for treatment-resistant systemic lupus erythematosus. (2021) (2)
Clinical significance of IgE in a large cohort of patients with moderate or severe chronic graft‐versus‐host disease (2017) (2)
High levels of FVIII and von Willebrand factor in chronic Graft-versus-Host Disease (2019) (2)
Assessing the Validity of the NIH Response Criteria for Chronic Graft-Versus-Host Disease (cGVHD): Consensus Measures Correlate with Clinical Outcomes, (2011) (2)
Achalasia in a Patient Undergoing Hematologic Stem Cell Transplant After Exposure to Tacrolimus (2017) (2)
Single-Cell RNA-Seq Identifies Potentially Pathogenic B Cell Populations That Uniquely Circulate in Patients with Chronic Gvhd (2019) (2)
Measurement of Oral Chronic Graft-Versus-Host Disease (2012) (2)
Prior Therapy with Rituximab Correlates with Less Acute Graft-Versus-Host Disease and Better Survival in B-Cell Lymphoma Patients Who Received Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT). (2007) (2)
Pilot Randomized Trial Comparing the Effects of Alemtuzumab and Cyclosporine Versus Tacrolimus, Methotrexate and Sirolimus on Graft Versus Host Disease Prevention, Engraftment and Immune Reconstitution After Reduced Intensity Unrelated Donor Transplantation. (2010) (2)
Evaluation of Scales Correlated With Clinician and Patient-Perceived Symptom Change in Ocular Graft-Versus-Host Disease: Results From the Chronic GVHD Consortium (2011) (2)
Association Of Graft Vs. Host Disease (GVHD) With a Lower Relapse/Progression Rate After Allogeneic Hemopoietic Stem Cell Transplantation (HSCT) With Reduced Intentsity Conditioning In Patients With Follicular and Mantle Cell Lymphoma: A Cibmtr Analysis (2013) (2)
Spiritual well-being in long-term survivors with chronic graft versus host disease after hematopoietic stem cell transplant. (2008) (2)
Chronic Graft versus Host Disease: Interdisciplinary Management: Diagnosis and Staging (2009) (2)
Chronic Graft versus Host Disease: Interdisciplinary Management: Plate section (2009) (2)
Trial in Progress: A Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309) (2019) (2)
Plasma Osteopontin Is a Biomarker Specifically Associated with Bronchiolitis Obliterans Syndrome after HCT (2016) (2)
Recommended Measures for Joint Chronic GVHD: Results from the Chronic GVHD Consortium (2012) (2)
Phase-2 Study of Pomalidomide in Advanced Corticosteroid-Resistant Chronic Graft-Versus-Host Disease (cGVHD). (2009) (2)
Second cancers early post allogeneic transplant: the case of ‘unrestrained’ malignancy? (2013) (1)
Correlation of Patient-Reported Outcomes with Clinical Organ Responses: Data from the Belumosudil Chronic Graft-versus-Host Disease Studies. (2022) (1)
HISTOPATHOLOGIC DIAGNOSIS OF CHRONIC GRAFT VERSUS HOST DISEASE 2014 NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: II. Pathology Working Group Report (2006) (1)
Feasibility and Reproducibility of the NIH Consensus Criteria To Evaluate Response in Chronic Graft Versus Host Disease (cGvHD). (2006) (1)
aGVHDAI: escape from the silo (2006) (1)
Recent Decrease in Acute GVHD and Increased Relapse in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants. (2007) (1)
The Balance of Effector and Regulatory Cell Populations in Oral Chronic GVHD: Potential Role of IL-15. (2007) (1)
Incidence of Epstein-Barr Virus (EBV) Detection in the Blood, Pre-Emptive Therapy, and EBV-Posttransplantation Lymphoproliferative Disorder (EBV-PTLD) after Allogeneic Hematopoietic Cell Transplantation (HCT) across a Broad Range of HCT Approaches and All Graft Sources (2019) (1)
33: Similar Graft-Versus-Leukemia Effect Using Matched Unrelated Donors, Compared to HLA-Identical Siblings for Hematopoietic Stem Cell Transplantation (2008) (1)
Influence of Graft Versus-Host Disease Prophylaxis Regimen On T-Cell Repertoire Diversity Following Reduced-Intensity HLA-Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation. (2012) (1)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report Transplantation and Cellular Therapy (2021) (1)
Development and Preliminary Testing Of The Post-Transplant Multimorbidity Index (PTMI) (2013) (1)
The ISHLT chronic lung allograft dysfunction consensus criteria are applicable to pulmonary chronic graft-versus-host disease (2022) (1)
"Regulating" rheumatoid arthritis via autotransplantation. (2008) (1)
Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials (2022) (1)
Immunotherapy and Chemotherapy Can Result in Long-Term Survival for Patients with Recurrent or Progressive Non-Hodgkin’s Lymphoma after Reduced-Intensity Allogeneic Stem Cell Transplantation. (2004) (1)
Early Diagnosis of Labial Fusion Enables Medical Treatment in an Office Setting (2015) (1)
HISTOPATHOLOGIC DIAGNOSIS OF CHRONIC GRAFT VERSUS HOST DISEASE: NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: II. The 2014 Pathology Working Group Report (2015) (1)
Alemtuzumab-Cyclosporine Versus Tacrolimus-Methotrexate-Sirolimus for Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors: Final Results of a Randomized Trial (2015) (1)
Phase II Clinical Experience with Dose-Adjusted EPOCH-Fludarabine, a Novel Regimen for Targeted Immune Depletion (TID) and Disease Control in Patients with Lymphoid Malignancies Prior to Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RIST). (2006) (1)
HPV32‐related Heck’s disease in a chronic graft‐versus‐host disease patient with long‐term successful KTP laser treatment: A rare case report (2021) (1)
Impact of Chronic GVHD on Late Relapse, Treatment Related Mortality and Survival After Allogeneic Hematopoietic Cell Transplantation for Hematological Malignancies (2012) (1)
Quality of Life and Chronic Gvhd Severity According to the NIH Criteria: Results From the Chronic Gvhd Consortium (2010) (1)
ORIGINAL ARTICLE Genetically identical twin transplantation for chronic lymphocytic leukemia (2007) (1)
Predictive Models Using NIH Criteria and Clinical Characteristics Define Diagnosis, Disease Activity and Risk Factors for Chronic Ocular Graft-Versus Host Disease (2015) (1)
Chronic GVHD Severity and Sensitivity to Change in Patient-Reported Quality of Life: Results From the Chronic GVHD Consortium (2011) (1)
Determinants and Clinical Significance of Musculoskeletal Symptoms in Patients With Chronic Graft-Versus-Host Disease (2022) (1)
Non-Ablative or Reduced Intensity Conditioning Regimens with Volunteer Unrelated Donor Progenitor Cell Transplantation. (2004) (1)
Development and Preliminary Usability and Accuracy Testing of the EBMT Gvhd App to Support Graft Versus Host Disease Diagnosis and Scoring According to NIH Criteria, By the EBMT Complications and Quality of Life Working Party (2015) (1)
T-Rapa6 and T-Rapa12 Cells Differentially Mediate Acute Gvhd after Low-Intensity Allogeneic HCT (2014) (1)
High Incidence of Osteoporosis in a Natural History Cohort of Patients with Moderate to Severe Chronic Graft-Versus-Host Disease and Risk Factor Analysis (2015) (1)
HLA DR15 Antigen Status Does Not Impact Graft-Versus-Host Disease or Disease-Free Survival in HLA-Matched Sibling Transplantation for Hematologic Malignancies (2011) (1)
Risk Factors for Major Transplant Related Outcomes In Pediatric Patients with Chronic Graft-Versus-Host Disease (2010) (1)
B regulatory cells and monocyte subpopulations in patients with chronic graft-vs-host disease (2021) (1)
Final Results of a Randomized Phase 2 Trial Evaluating Lower-Dose Versus Higher-Dose Pomalidomide as Therapy for Corticosteroid-Refractory Chronic Gvhd (2016) (1)
A new standard in GVHD prophylaxis? An introduction to BMT CTN 1703. (2020) (1)
Soluble BAFF Is Elevated Following Allogeneic SCT but Is Not an Early Predictor for the Development of cGVHD. (2007) (1)
Comprar Chronic Graft Versus Host Disease | Georgia B. Vogelsang | 9780521884235 | Cambridge University Press (2009) (1)
Calculated NIH Response Correlates with Changes in Patient-Reported Symptoms but Not with Quality of Life: Results From the Chronic Gvhd Consortium (2011) (1)
Characterization of Hepatic Dysfunction in subjects diagnosed with Chronic GVHD by NIH Consensus Criteria. (2022) (1)
Comorbidity Significantly Impairs Quality Of Life In Patients After Allogeneic Hematopoietic Stem Cell Transplantation – Results From The Prospective German Multicenter Validation Trial (2013) (1)
Pilot Study of Radiation-Targeted Donor Lymphocyte Infusion for Cancer Progression after Allogeneic Hematopoietic Stem Cell Transplantation (2015) (1)
Leukapheresis Safely and Effectively Yields Lymphocyte Populations Sufficient for Chronic Gvhd Research (2015) (1)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report Transplantation and Cellular Therapy (2021) (1)
Change in NIH Skin Score 0–3 Correlates with Provider- and Patient-Reported Skin Changes and Overall Survival: Results From the Chronic Gvhd Consortium (2011) (1)
Von Willebrand Factor and Factor VIII as potential biomarkers of chronic Graft-versus-Host Disease (2015) (1)
Glycoprotein YKL-40: a novel biomarker of chronic graft-vs-host disease activity and severity? (2016) (1)
All-Trans Retinoic Acid (ATRA) Targets IRF4 Deficient, NOTCH2-Activated B Cells from Chronic Gvhd Patients (2016) (1)
Occupational Participation and Quality of Life in Persons With Chronic Graft-Versus-Host Disease (cGVHD): An Exploratory Study (2019) (1)
Chronic graft-versus-host disease: Consensus, challenges, and controversies (2017) (1)
Predictors of Hematologic Malignancy Relapse in Patients with Advanced Chronic Graft-versus-Host Disease (2021) (0)
FLT Imaging Reveals Kinetics and Biology of Engraftment after Myeloablative HSCT (2014) (0)
346: Homeostatic and Inflammatory Processes Contribute to Elevated Plasma Levels of B Cell Activating Factor (BAFF) in Chronic Graft Versus Host Disease (CGVHD) (2008) (0)
Significant Associations of IgG Glycan Structures With Chronic Graft-Versus-Host Disease Manifestations: Results of the Cross-Sectional NIH Cohort Study (2021) (0)
Graft-vs-host disease (2005) (0)
Chronic Graft-Versus-Host Disease Abrogates Standard Risk Factors for Malignancy Relapse after Allogeneic Hematopoietic Stem Cell Transplantation (2019) (0)
Risk Factors for Acute Graft-Versus-Host Disease (GvHD) after Related Donor HLA-Matched Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Adult Leukemia: Identification of Modifiable and Non-Modifiable Factors. A CIBMTR Study. (2007) (0)
Imatinib mesylate for the treatment of sclerotic skin chronic graft-versus-host disease (2012) (0)
NHANES III Equations for PFT Interpretation Significantly Alter the Number of BOS Diagnoses After Hematopoietic Stem Cell Transplantation (HSCT) (2010) (0)
Immune reconstitution in cGVHD patients-a pilot study (2015) (0)
Preemptive T-Rapa Cell DLI after Low Intensity Allogeneic HCT May Allow for Improved Overall Survival in High Risk Lymphoid Malignancies (2016) (0)
Health Economics of Steroid Refractory Chronic Graft-Versus-Host-Disease Treatments: Cost-Utility Based Meta-Analysis (2017) (0)
Correction: Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease—results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health (2021) (0)
A National Multi-Center Randomized Study to Assess the Accuracy, Reliability, and User Satisfaction of the Ebmt Gvhd App in Graft Versus Host Disease Assessment (2018) (0)
Long term off-line extracorporeal photochemotherapy for chronic graft-vs-host disease: a 9 year single center experience (2016) (0)
Interim Analysis of KD025-213: A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) after at Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study; NCT03640481) (2020) (0)
Burden of Illness in Chronic Graft vs. Host Disease - A Prospective Cohort Study. (2007) (0)
Generation of a Platform for Identification of CLL Specific Cell Surface Proteins Targeted by Anti-Tumor Antibodies in Patient Sera After Allogeneic Hematopoietic Cell Transplantion (2012) (0)
The ‘EBMT GVHD App' Improves the Accuracy of Graft-Versus-Host-Disease Assessment According to NIH Criteria Compared to Standard Practice (2016) (0)
Oral Candida species colonization in chronic Graft-versus-Host Disease (2015) (0)
A Randomized Phase 2 Placebo Controlled Trial of Clobetasol Rinse for Treatment of Oral Chronic Graft-Versus-Host Disease (2016) (0)
Autologous Rapamycin-Resistant T Cell Therapy of Multiple Myeloma (2016) (0)
Polineuropatija u bolesnika s kroničnom reakcijom davatelja protiv primatelja nakon alogene transplantacije krvotvornih matičnih stanica- preliminarni rezultati prospektivne studije (2014) (0)
Abstracts from Scientific Programme (2010) (0)
Immunotherapy for acute leukemia (2015) (0)
Severe Ocular Graft-Versus-Host Disease Successfully Treated with Amniotic Membrane Transplantation - Case Series (2017) (0)
Collection of peripheral blood mononucleated cells for chronic graft-versus-host disease immunology research: safety and effectiveness of leukapheresis in 132 patients (2022) (0)
ncillary Therapy and Supportive Care of Chronic raft-versus-Host Disease : National Institutes of ealth Consensus Development Project on Criteria or Clinical Trials in Chronic Graft-versus-Host isease : V . Ancillary Therapy and Supportive Care orking Group Report (2006) (0)
Do anti-mullerian hormone levels predict ovarian reserve in SLE patients presenting for hematopoietic stem cell transplant? (2007) (0)
Abnormal liver tests are not sufficient for diagnosis of hepatic graft‐versus‐host disease in critically ill patients (2022) (0)
Effects of Alvelestat, an Oral Neutrophil Elastase Inhibitor, on Elevated Elastase and Collagen Turnover Biomarkers in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation (2021) (0)
Pre-Emptive T-Rapa Cell DLI for Therapy of High-Risk Lymphoma After Low-Intensity Allogeneic HCT (2012) (0)
Oral Symptom Experience and Health-Related Quality of Life of Adult Survivors of Hematopoietic Stem Cell Transplantation (HSCT) with Chronic Graft-Versus-Host-Disease (cGVHD) (2011) (0)
Quality of life in long-term survivors after hematopoietic stem cell transplantation (2015) (0)
Factors affecting nutritional status in chronic GVHD (2019) (0)
Small fiber neuropathy in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation - preliminary results of a prospective study (2014) (0)
Association of Comorbidity Scoring with Outcome in Patients with Chronic Graft Versus Host Disease (2013) (0)
OI0400 Oral graft-vs-host disease is distinguished by inflammation and impaired antimicrobial immunity (2014) (0)
Chronic gvhd dictionary—eurograft cost action initiative consensus report (2022) (0)
Consensus Grading for Cytokine Release Syndrome and Neurologic D 224 X X Toxicity Associated with Immune Effector Cells (2019) (0)
Immune responses following G-CSF mobilized allogeneic blood stem cell transplantation (2000) (0)
Comparison of Proposed NIH Response Criteria with Clinician-Reported Changes in Organ-Specific and Overall Response (2011) (0)
Development, preliminary usability and accuracy testing of the EBMT “eGVHD App” to support graft versus host disease assessment according to NIH criteria – a proof of concept (2016) (0)
Plasma Cytokine Levels Distinguish Chronic Graft Versus Host Disease (cGVHD) Symptom Profile Groups (2009) (0)
Limited Usefulness of Bronchoalveolar Lavage (BAL) in the Diagnosis of Pulmonary Infiltrates after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) (2015) (0)
Immune Correlates from a Prospective Trial Suggest Leukotriene Signaling and Alternative Macrophage Activation in Clinical Bronchiolitis Obliterans Syndrome (2021) (0)
Graft-Versus-Leukemia Effect Is Equivalent in Recipients of Matched Sibling and Matched Unrelated Donor Conventional Hematopoietic Cell Transplant. (2007) (0)
Comorbidity Burden in Patients with Chronic Graft Versus Host Disease (2014) (0)
Human Th17 activity profile in oral chronic Graft-versus-Host Disease (2017) (0)
354: Elevated Levels of CD19+ CD21- Transitional B cells in Chronic Graft Versus Host Disease (CGVHD) Associated with Elevated Plasma BAFF Levels and BAFF Receptor Expression (2008) (0)
Role of Clinical Laboratory Markers of inflammation in Assessing Chronic Graft Versus Host Disease (cGVHD) Activity and Severity (2011) (0)
PF773 LOWER SERUM LEVELS OF ZINC AND MAGNESIUM ARE ASSOCIATED WITH WORSE ORAL CGVHD AND DYSGEUSIA IN CGVHD PATIENTS (2019) (0)
Infectious Complications After Unrelated Donor Allogeneic Hematopoietic Cell Transplantation With Or Without Alemtuzumab Based In Vivo Lymphocyte Depletion (2013) (0)
Procjena promjena u usnoj šupljini u bolesnika s kroničnom reakcijom transplantata protiv primatelja (cGVHD) (2014) (0)
Clinical and Immunologic Characteristics of Patients with Chronic Graft-Versus-Host Disease Persisting Seven or More Years after Diagnosis (2015) (0)
Targeted immune depletion prior to reduced-intensity allogeneic stem cell transplantation results in rapid and complete donor chimerism with low treatment-related mortality. (2006) (0)
Late Pneumocystis Pneumonia After HSCT: Atypical Presentation and Lack of Correlation with CD4 Count (2013) (0)
The CIBMTR Chronic GVHD Risk Group Predicts Major Outcomes In An Independent Validation Cohort (2013) (0)
Mucosal T-Bet+CD8+T cells are implicated in the pathogenesis of human chronic Graftversus- Host Disease (2017) (0)
DLI Therapy Using T-Rapa Cells: Graft-Versus-Lymphoma and GvHD Effects (2016) (0)
transplantation Risk factors for acute GVHD and survival after hematopoietic cell (2012) (0)
26: Epithelial Apoptosis in Oral Chronic GVHD is Mediated by Effector-Memory CD8 cells: Potential Role of IL-15 (2008) (0)
RDW Is an Independent Prognostic Biomarker in Patients with Chronic Graft-Versus-Host-Disease (2022) (0)
Importance of gynecological examination in female patients with chronic graft versus host disease (2015) (0)
A Young Man with Lymphocytosis (1999) (0)
Hematopoietic Stem Cell Transplantation (2020) (0)
Clinical Characterization and Cytokine Profile of Fatigue in Patients with Chronic Gvhd (2019) (0)
Safety and Efficacy of Cytotoxic Chemotherapy after Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Hematologic Malignancy. (2006) (0)
Oral chronic graft-versus-host disease symptom experience and cytokine correlates in survivors after transplantation for hematologic malignancies (2007) (0)
Prevalence of Joint Deficit Among Chronic Gvhd Patients Who Do Not Manifest Cutaneous or Fascial Sclerosis (2014) (0)
Hepatic Complications of Hematopoietic Stem Cell Transplantation (2013) (0)
Reduced-intensity allogeneic stem cell transplantation for diffuse large B-cell lymphoma: Clinical evidence of a graft-versus-lymphoma effect. (2006) (0)
Influence Of Organ Scores On Mortality In Chronic GVHD: Results From The Chronic GVHD Consortium (2013) (0)
Salivary Zymogen Granule Protein 16B Drops at Onset of Chronic Graft-Versus-Host Disease: A Possible Salivary Biomarker for Oral Chronic Graft-Versus-Host Disease (2019) (0)
Incidence and risks for sclerodermatous chronic grafi versus-host disease after allogeneic marrow or bloo1 transplantation (2000) (0)
Prospective phase II trial of montelukast to treat bronchiolitis obliterans syndrome after hematopoietic cell transplant and investigation into BOS pathogenesis. (2022) (0)
Significant association of IgG glycan structures with intensity of immunosuppression among chronic graft-versushost disease patients: results of the NIH cohort study (2017) (0)
Amending NIH Consensus Criteria for the Clinical Diagnosis of Bronchiolitis Obliterans After HSCT (2009) (0)
Natural killer cell receptor repertoire following HLA-matched allogeneic hematopoietic stem cell transplantation (2004) (0)
transplantation superior to HLA-identical siblings for hematopoietic stem cell The graft-versus-leukemia effect using matched unrelated donors is not (2011) (0)
Hepatic Complications (0)
Overlap Subtype of Chronic GVHD Is Associated with Adverse Prognosis, Functional Impairment, and Inferior Patient Reported Outcomes: A Chronic GVHD Consortium Study (2012) (0)
Phase 1 Study of Alvelestat, an Oral Neutrophil Elastase Inhibitor, in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation (2020) (0)
A Prognostic System Predictive of Outcomes in Persons Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome (2015) (0)
Quantitative Salivary Proteomic Differences in Oral Chronic Graft-versus-Host Disease (2012) (0)
Incidence, Risks, and Outcomes of Relapse Following Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma. (2010) (0)
Pleuroparenchymal Fibroelastosis in Patients with Chronic Graft-Versus-Host-Disease: A Rare Delayed Complication of Hematopoietic Stem Cell Transplantation (2022) (0)
Ocular Surface Changes After Hematopoietic Stem Cell Transplant (HSCT): The Shifting Clinical Spectrum of Ocular Graft Versus Host Disease (oGVHD) (2007) (0)
A New Diagnostic Classification Tool for Pulmonary Chronic Graft-Versus-Host-Disease: Adaptation of the International Society for Heart and Lung Transplantation Chronic Lung Allograft Dysfunction Consensus Criteria (2021) (0)
Physician-Reported CR+PR at 6 Months Predicts Subsequent Survival in Patients with Chronic GVHD (2015) (0)
Allogeneic Bone Marrow Transplantation for Primary Immunodeficiencies: Pilot Trial of a Novel, Reduced Intensity Platform (2017) (0)
Elevated PTH levels among chronic Graft-versus-Host Disease patients and other long term survivors after allogeneic hematopoietic stem cell transplantation (2020) (0)
Nonmyeloablative allogeneic stem cell transplantation (NST) for lymphoid malignancies using pentostatin/low-dose total body irradiation (2004) (0)
Preliminary Results of a Phase II Trial of Montelukast for the Treatment of Bronchiolitis Obliterans Syndrome After HSCT (2010) (0)
A Large Cohort Comparison of the New 2014 National Institutes of Health Chronic Graft-Versus-Host Disease Staging Criteria with the 2005 Version in Severely Affected Patients (2018) (0)
Targeting the Human Notch 2-BCR Axis: A Driver of B-Cell Hyper-Responsiveness in Active Chronic Graft-Versus Host Disease (cGVHD) (2015) (0)
Utility of Grip Strength and 2 Minute Walk Test in Chronic GVHD Assessment: An Analysis From the Chronic GVHD Consortium (2013) (0)
Phase II Pilot Study of Imatinib Mesylate for the Treatment of Severe Sclerotic Skin Chronic Graft Versus Host Disease (ScGVHD) (2012) (0)
A Cross-sectional Comparison of Magnetic Resonance Imaging Findings and Clinical Assessment in Patients With Morphea (2020) (0)
Pulmonary symptoms measured by the NIH Lung score predict overall survival, non-relapse mortality and patient-reported outcomes in chronic GVHD (2014) (0)
Biomarkers for Chronic Graft-versus-Host isease : National Institutes of Health Consensus evelopment Project on Criteria for Clinical Trials n Chronic Graft-versus-Host Disease : III . Biomarker orking Group Report (2006) (0)
Quality of Life after Hematopoietic Stem Cell Transplantation in Patients with Chronic Graft- Versus-Host Disease (2016) (0)
Haemopoietic Stem Cell Transplantation for Rheumatoid Arthritis—World Experience and Future Trials (2019) (0)
Chronic Gvhd Global Severity According to NIH Consensus Criteria: Results From the Chronic Gvhd Consortium (2010) (0)
Ocular Gvhd: Epidemiology, Risk Factors and Impact on Quality of Life-a Chronic Gvhd Consortium Study (2014) (0)
Correlations among vitality, physical competence, lipid profile and measures of inflammation in transplant survivors with chronic graft versus host disease (2007) (0)
B Cell Deficiency and CD21low B Cells As Markers For Measuring Cgvhd Severity and Activity In a Large Patient Cohort (2013) (0)
Demographic and clinical characteristic of female patients with genital cGVHD (2015) (0)
Determinants of Platelet Counts in Patients with Chronic Graft Versus Host Disease. (2009) (0)
Recommended Tools for Joint Chronic Graft-Versus-Host Disease: Results From the Chronic Gvhd Consortium (2012) (0)
B ational Institutes of Health Consensus Development roject on Criteria for Clinical Trials in Chronic raft-versus-Host Disease : I . Diagnosis and Staging orking Group Report (2005) (0)
Implementation of NIH Criteria for Standardization of Chronic Graft-Versus-Host Disease in Croatia: Two-Year Experience (2015) (0)
FAM treatment for new onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation (2016) (0)
Outcomes of HLA Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative vs. Reduced-Intensity Conditioning Regimens (2014) (0)
Early Experience with a Radiation- and Serotherapy-Free Reduced Intensity Conditioning Platform for Allogeneic Bone Marrow Transplantation (alloBMT) in Primary Immunodeficiency (PID) (2018) (0)
Role Of Interferon-Induced Processes In Lichenoid Skin Inflammation In Chronic Graft Versus Host Disease (2010) (0)
Minor Histocompatibility Antigen Mismatch and Incidence of Graft Versus Host Disease, Event-Free, and Overall Survival in Patients Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (2012) (0)
Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309 (2022) (0)
Abstract A071: Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes (2019) (0)
Natural killer cell receptor repertoire following HLA-matched allogeneic hematopoietic stem cell transplantation. (2004) (0)
Single-cell Landscape Analysis Unravels Molecular Programming of the Human B Cell Compartment in Chronic GVHD (2023) (0)
Allogeneic Hematopoetic Transplantation for CLL: Results of Combination Chemotherapy as Pre-Transplant Targeted Lymphocyte Depletion on Disease Response, Donor Chimerism, and Transplantation Outcomes. (2010) (0)
Regulatory B Cells Deficiency in Sclerotic-Type Cutaneous Chronic Graft-Versus-Host Disease (2014) (0)
51-OR: RELATIONSHIP BETWEEN HLA RESTRICTED MINOR HISTOCOMPATIBILITY ANTIGENS AND GRAFT VERSUS HOST DISEASE IN PATIENTS FOLLOWING MATCHED UNRELATED PERIPHERAL BLOOD STEM CELL ALLOGRAFTS (2012) (0)
Gastrointestinal complications (0)
OP41 Chronic graft versus host disease: new approaches for transplant greatest challenges (2007) (0)
BAFF, CXCL9 and CCL15 in Different Clinical Chronic Graft Versus Host Disease Phenotypes (2021) (0)
Salivary ZG16B Expression Loss Marks Onset of Oral Chronic Graft-Versus-Host Disease and Exocrine Gland Dysfunction (2021) (0)
Validation of the National Institutes of Health (NIH) Consensus Criteria for Chronic GVHD (cGVHD) Staging Correlated With Established Indicators of Disease Severity and Prognosis (2011) (0)
1568 Identification of fibroinflammatory and fibrotic transcriptomic subsets of human sclerotic cutaneous chronic graft-versus-host disease (2023) (0)
Human herpesviruses in oral chronic Graft-versus- Host Disease (2016) (0)
Human pSTAT3-Inhibited Itregs Prevent Gvhd, Maintain Anti-Leukemia Immunity, and Increase Their Potency after Metabolic Reprogramming (2020) (0)
Pulmonary Symptoms Measured by the NIH Lung Score Predict Overall Survival and Non-Relapse Mortality in Chronic GVHD (2013) (0)
228: Nonmyeloablative allogeneic stem cell transplantation (NST) for hematologic malignancies (HM) using pentostatin/low-dose total body irradiation (Pt-TBI) (2007) (0)
EPOCH-FR: A novel salvage regimen for patients with lymphoid malignancies being considered for reduced-intensity allogeneic hematopoietic stem cell transplantation. (2010) (0)
Evaluation of Congruency between Patient and Clinician Chronic Graft-Versus-Host Disease Severity Assessment (2021) (0)
Correlation of the NIH and Vienna Skin Scores with Provider and Patient-Reported Skin Changes in Chronic Graft-Versus-Host Disease (GVHD). (2009) (0)
Chronic Graft versus Host Disease: Interdisciplinary Management: Preface (2009) (0)
A Phase 1 Single Dose Escalation Study of Palifermin Administered Pre-Transplant Conditioning in Subjects Undergoing Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation (2020) (0)
Factors Associated with Subsequent Cancers in Patients with Moderate or Severe Chronic Graft-Versus-Host Disease after Transplant for Hematologic Malignancy (2019) (0)
Pathogenic Shifts in the Oral Microbiome Are Associated with Onset of Oral Mucosal Chronic Graft-Versus-Host-Disease (2021) (0)
CHAPTER 19 – Autoimmune disorders (2009) (0)
Should patients with chronic GVHD take vitamin D supplementation? A cross sectional natural history cohort study (2015) (0)
CD34-selected versus unmanipulated grafts for severe rheumatoid arthritis: comment on the article by Moore et al. (2003) (0)
Correction: Ocular surface indicators and biomarkers in chronic ocular graft-versus-host disease: a prospective cohort study (2021) (0)
Durable discontinuation of systemic therapy for chronic graft-versus-host disease: myth or reality? (2022) (0)
Association of NIH organ cGVHD scores with blood lymphocyte subsets – a pilot study (2015) (0)
A Randomized Placebo Controlled Double Masked Clinical Trial of Autologous Serum Eye Drops for severe Ocular Graft Versus Host Disease (GVHD) (2017) (0)
Sarcopenia in cgvhd patients (2018) (0)
Erratum to "Salivary Gland Involvement in Chronic Graft-versus-Host Disease: Prevalence, Clinical Significance, and Recommendations for Evaluation" [Biol Blood Marrow Transplant 16:1362-1369]. (2016) (0)
Quality of Life in Patients With Skin of Color and Chronic Graft-vs-Host Disease. (2020) (0)
disease: a multicenter study Performance of a new clinical grading system for chronic graft-versus-host (2013) (0)
NHANES III Equations for PFT Interpretation Significantly Alters BOS Diagnoses, Severity, and Prognosis After Hematopoietic Stem Cell Transplantation (HSCT) (2011) (0)
Ocular chronic GVHD in clinical transplant practice luid dynamics and ocular perfusion pressure (2016) (0)
Predictors for Permanent Discontinuation of Systemic Immunosuppression in Patients with Moderate to Severe Chronic Graft-Versus-Host-Disease (2016) (0)
Abstract CT138: Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes (2021) (0)
Prospective Phase Ii Trial of Montelukast to Treat Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation and Investigation into Bos Pathogenesis (2021) (0)
Glycoprotein YKL40 : a Novel Biomarker of Chronic Graft Versus Host Disease Activity? (2016) (0)
Distinct MYC thresholds in hematopoietic neoplasia Enforced transgenic expression of c-MYC causes monocytic neoplasms in heterozygous transgenic mice but T-cell lymphomas in homozygous transgenic mice, demonstrating that tuned thresholds of induce neoplastic (2006) (0)
A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display Category : Transplantation Running head : Mining antibody repertoires after transplantation (2009) (0)
Gastrointestinal Complications of Hematopoietic Cell Transplantation (2013) (0)
FoxP3+Regulatory T Cells In Blood And Tissues In Chronic Graft Versus Host Disease (2010) (0)
Concurrent Fludarabine and Cyclophosphamide As a Reduced Intensity Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation Ablates Host T-Cells and Results in Rapid Full Donor Chimerism (2011) (0)
Implementation and dissemination of chronic Graft-versus-Host Disease NIH criteria and recommendations - formation of a multidisciplinary team and program at the University Hospital Center Zagreb, Croatia (2014) (0)
Th17 Recruitment and Interferon Pathway Activation in Oral Chronic Graft-Versus-Host Disease Tissues (2016) (0)
A starting point for the phenotypic classification of pulmonary chronic graft-versus-host disease (2022) (0)
Factors Associated with Fatigue in Chronic Graft-Versus-Host Disease (2014) (0)
Belumosudil for Patients with Chronic Graft-Versus-Host Disease: Combined Analysis of Failure-Free Survival (FFS) in the KD025-208 and Pivotal Rockstar Trials (2021) (0)
granulocyte colony-stimulating factor: association with donor characteristics Decreased immune functions of blood cells following mobilization with (2013) (0)
Commentary (Pavletic): Nonmyeloablative Preparative Regimens for Allogeneic Hematopoietic Transplantation (2003) (0)
375: Hematopoietic stem cell transplantation for systemic lupus erythematosus: Unique challenges and strategies for the nursing care team (2007) (0)
burden of disease Sclerotic-type chronic GVHD of the skin : clinical risk factors , laboratory (2011) (0)
New Therapeutic Options for Chronic Lymphocytic Leukemia (2007) (0)
Use of Targeted Lymphocyte Depletion as a Personalized Approach to Improve Engraftment and Disease Control Following Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Unrelated Donors (2010) (0)
Pilot Clinical Trial of Lymphocyte-Selective Pentostatin Plus Cyclophosphamide Conditioning, High Dose Sirolimus and Pre-Emptive DLI with Rapamycin-Resistant Donor CD4+ T Cells (2015) (0)
Multi-Center Phase I Study of Th1/Tc1 Immunotherapy Following Autologous Hematopoietic Progenitor Cell Transplantation in Reccurrent or High Risk Plasma Cell Myeloma (2013) (0)
Increased Type I Interferon Signaling and Inflammatory Factors Associated with T-Bet+ Cytotoxic Effectors in Chronic Graft Versus Host Disease of Oral Mucosa. (2008) (0)
Forty years of hematopoietic stem cell transplantation in Croatia: First-World options and First-World science. (2023) (0)

This paper list is powered by the following services:

Other Resources About Steven Z. Pavletic

en.wikipedia.org

What Schools Are Affiliated With Steven Z. Pavletic?

Steven Z. Pavletic is affiliated with the following schools:

Image Attributions

Image Source for Steven Z. Pavletic